Role Of Bak And Bax Membrane Anchors In Targeting And Apoptotic Pore Formation.
Funder
National Health and Medical Research Council
Funding Amount
$352,319.00
Summary
In cancer cells the normal process of cell death (called apoptosis) is defective, helping abnormal cells to grow and multiply unchecked. The Bak and Bax proteins are members of the Bcl-2 family of apoptosis regulators, and play a pivotal role in mediating cell death. By defining how these proteins form a pore in mitochondria, the point of no return in cell death, will help the development of novel anti-cancer agents that target the Bcl-2 family in general, and Bak and Bax in particular.
Apo2L/TRAIL Killing Of Tumour Cells And The Role Of Inhibitor Of Apoptosis Proteins
Funder
National Health and Medical Research Council
Funding Amount
$390,321.00
Summary
Melanomas and Gliomas are tumour types that respond poorly to current treatments. Current treatments are not only sometimes ineffective, but also unpleasant and may cause co-lateral damage. We will test 2 new targetted anti-cancer treatments, that so far appear to have minor side effects in small animal models, on these difficult to treat tumour types to see if and how they kill them. We also want to know whether these independent treatments can work together to kill tumours more effectively. Al ....Melanomas and Gliomas are tumour types that respond poorly to current treatments. Current treatments are not only sometimes ineffective, but also unpleasant and may cause co-lateral damage. We will test 2 new targetted anti-cancer treatments, that so far appear to have minor side effects in small animal models, on these difficult to treat tumour types to see if and how they kill them. We also want to know whether these independent treatments can work together to kill tumours more effectively. Although we will not personally test these drugs in clinical settings, these drugs or similar are currently in preclinical and clinical trials. This means that understanding how these drugs function is of paramount importance and may result in better clinical trials and possibly more rapid acceptance of the use of these drugs in patients.Read moreRead less
I am a cancer researcher trained in cell biology, immunology and molecular oncology. I made major contributions to the discoveries that defects in cell death can cause cancer, autoimmune disease and impair the response of cancers to chemotherapy. My current work aims to reach a detailed understanding of the molecular mechanisms of programmed cell death and to exploit this knowledge to develop novel therapeutics for cancer and autoimmune diseases that can directly activate this process.
The Potential Of Blocking Translation Initiation For Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$347,792.00
Summary
Treatment of many cancers remains unsatisfactory and new drugs for treating them are urgently required. By determining how a new class of anti-cancer drugs kills cancer cells and whether they might also affect normal cells, we can determine how they can be optimally given to patients suffering from cancer.
How The Bcl-2 Protein Family Controls Apoptosis And Impacts On Cancer Development And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$850,346.00
Summary
Impaired cell death (apoptosis) is now recognized as an important step towards cancer and a major barrier to effective therapy. The discoveries on apoptosis by Professor Jerry Adams and colleagues have galvanized the search for drugs that engage the cell’s apoptotic machinery as a new way to treat cancer. His proposed studies aim to clarify how apoptosis is controlled and how the control goes awry in cancer, and to determine how such drugs can be most effectively used to improve cancer treatment ....Impaired cell death (apoptosis) is now recognized as an important step towards cancer and a major barrier to effective therapy. The discoveries on apoptosis by Professor Jerry Adams and colleagues have galvanized the search for drugs that engage the cell’s apoptotic machinery as a new way to treat cancer. His proposed studies aim to clarify how apoptosis is controlled and how the control goes awry in cancer, and to determine how such drugs can be most effectively used to improve cancer treatment.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100091
Funder
Australian Research Council
Funding Amount
$250,000.00
Summary
A five laser multichannel flow cytometry cell sorter for the University of New South Wales as part of an advanced flow cytometry network. Flow cytometry is a technique for counting and examining microscopic particles, such as cells and chromosomes, by suspending them in a stream of fluid and passing them by an electronic detection apparatus. This project will establish such advanced cell sorting instrumentation at the University of New South Wales, providing this capability to a wide range of re ....A five laser multichannel flow cytometry cell sorter for the University of New South Wales as part of an advanced flow cytometry network. Flow cytometry is a technique for counting and examining microscopic particles, such as cells and chromosomes, by suspending them in a stream of fluid and passing them by an electronic detection apparatus. This project will establish such advanced cell sorting instrumentation at the University of New South Wales, providing this capability to a wide range of researchers in diverse fields. The project will also provide a basis for establishing a flow cytometry network with partner institutes University of Sydney and the University of Technology, Sydney.Read moreRead less
Sphingosine-1-phosphate receptor 5: a novel regulator of T cell immunity. T cells provide critical immune protection against infection and cancer. However, the pathways that regulate these immune cells are not fully understood. T cells express a molecule called S1P5 that has an unknown function in these cells. In this proposal, we reveal new evidence that this molecule is an unappreciated and crucial regulator of T cell behaviour. Using state-of-the-art techniques and novel genetic tools, this p ....Sphingosine-1-phosphate receptor 5: a novel regulator of T cell immunity. T cells provide critical immune protection against infection and cancer. However, the pathways that regulate these immune cells are not fully understood. T cells express a molecule called S1P5 that has an unknown function in these cells. In this proposal, we reveal new evidence that this molecule is an unappreciated and crucial regulator of T cell behaviour. Using state-of-the-art techniques and novel genetic tools, this project aims to discover the involvement of S1P5 in the immune response, and determine how S1P5 can be controlled to enhance protective T cell immunity. The expected outcomes are to generate fundamental new knowledge that will have significance for regulation of the immune response. Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE110100172
Funder
Australian Research Council
Funding Amount
$330,000.00
Summary
Comprehensive cell imaging facility. This facility will provide Australian biological science researchers with equipment for in-depth analyses of cell function in vitro and in vivo. It will enable innovative research targeted at important questions in fields including cancer, immunology, stem cell biology, infectious disease and tissue regeneration.
Dual Targeting Of Myc And Apoptosis Pathways For Improved Blood Cancer Treatment Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$754,685.00
Summary
Cancer cells frequently possess defects in genes called MYC and BCL-2 that control their growth and survival. Our preliminary studies have shown that combining novel reagents that specifically target MYC plus BCL-2 leads to enhanced lymphoma cell killing. In the proposed research, we will further develop these reagents and evaluate their ability to treat blood cancer in mice. We expect our approach will provide new avenues for treating cancer patients that respond poorly to current treatments.
Mechanisms Of Mcl-1- And Bcl-2-mediated Resistance To Apoptosis
Funder
National Health and Medical Research Council
Funding Amount
$439,796.00
Summary
Anti-cancer therapies that target either the mitochondrial or death receptor pathways of apoptotic cell death are being developed and in clinical trials. In certain cancer cells, the tBid protein links the two pathways, making the death receptor pathway dependent on the mitochondrial pathway. Our studies will test how tBid links the two pathways and how the link might be bypassed, potentially indicating means of improving the effectiveness of treating cancer by targeting death receptors (e.g. TR ....Anti-cancer therapies that target either the mitochondrial or death receptor pathways of apoptotic cell death are being developed and in clinical trials. In certain cancer cells, the tBid protein links the two pathways, making the death receptor pathway dependent on the mitochondrial pathway. Our studies will test how tBid links the two pathways and how the link might be bypassed, potentially indicating means of improving the effectiveness of treating cancer by targeting death receptors (e.g. TRAIL).Read moreRead less